- Home
- ADEA vs AUPH Comparison
ADEA vs AUPH Comparison
Compare ADEA & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADEA
- AUPH
- Stock Information
- Founded
- ADEA 1990
- AUPH 1993
- Country
- ADEA United States
- AUPH Canada
- Employees
- ADEA N/A
- AUPH N/A
- Industry
- ADEA Computer Software: Prepackaged Software
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- ADEA Technology
- AUPH Health Care
- Exchange
- ADEA Nasdaq
- AUPH Nasdaq
- Market Cap
- ADEA 1.3B
- AUPH 1.3B
- IPO Year
- ADEA N/A
- AUPH 1999
- Fundamental
- Price
- ADEA $13.66
- AUPH $9.03
- Analyst Decision
- ADEA Strong Buy
- AUPH Strong Buy
- Analyst Count
- ADEA 2
- AUPH 3
- Target Price
- ADEA $17.00
- AUPH $10.33
- AVG Volume (30 Days)
- ADEA 656.6K
- AUPH 1.5M
- Earning Date
- ADEA 02-18-2025
- AUPH 02-13-2025
- Dividend Yield
- ADEA 1.46%
- AUPH N/A
- EPS Growth
- ADEA N/A
- AUPH N/A
- EPS
- ADEA 0.37
- AUPH N/A
- Revenue
- ADEA $343,723,000.00
- AUPH $220,361,000.00
- Revenue This Year
- ADEA N/A
- AUPH $36.97
- Revenue Next Year
- ADEA $8.69
- AUPH $16.43
- P/E Ratio
- ADEA $36.90
- AUPH N/A
- Revenue Growth
- ADEA N/A
- AUPH 38.72
- 52 Week Low
- ADEA $9.68
- AUPH $4.71
- 52 Week High
- ADEA $14.75
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- ADEA 56.26
- AUPH 51.75
- Support Level
- ADEA $13.71
- AUPH $9.22
- Resistance Level
- ADEA $14.64
- AUPH $9.76
- Average True Range (ATR)
- ADEA 0.58
- AUPH 0.44
- MACD
- ADEA 0.02
- AUPH -0.10
- Stochastic Oscillator
- ADEA 54.49
- AUPH 16.33
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property Licensing (IP). In the IP segment, it primarily license innovations to leading companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.